Cambia (diclofenac potassium) NDC 13913-012

NDC codes

FDA NDC Directory

Product NDC (as listed)13913-012Labeler and product segments. Claims need a package NDC.

Product NDC at billing width13913-0012Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
13913-012-02	13913001202	9 PACKET in 1 CARTON (13913-012-02) / 1 POWDER, FOR SOLUTION in 1 PACKETMarketed from Mar 10, 2016
13913-012-03	13913001203	9 PACKET in 1 CARTON (13913-012-03) / 1 POWDER, FOR SOLUTION in 1 PACKET (13913-012-01)Marketed from Mar 10, 2016

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cambia
Generic name (nonproprietary): diclofenac potassium
Active ingredients: Diclofenac potassium — 50 mg/1
Dosage form: Powder, For solution
Route: Oral
Labeler: Assertio Therapeutics, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 022165
Marketing start: Mar 10, 2016
Listing expires: Dec 31, 2026
Other FDA classes: Non-Steroidal (Chemical structure)Cyclooxygenase Inhibitors (Mechanism)Decreased Prostaglandin Production (Physiologic effect)
Identifiers: Product ID 13913-012_b9a3d927-3dc3-4860-ac3b-3dd20df47dd6SPL ID b9a3d927-3dc3-4860-ac3b-3dd20df47dd6SPL set ID d249ced1-4ca0-4f57-adcb-23440f58f659RxCUI 859063, 859066UNII L4D5UA6CB4
Pharmacologic class: Nonsteroidal Anti-inflammatory Drug

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N413913001202 followed by a unit qualifier and the quantity

Package 13913-0012-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 11, 2024. This label includes a boxed warning.

Indications (excerpt from the label)

CAMBIA is indicated for the acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Limitations of Use: CAMBIA is not indicated for the prophylactic therapy of migraine. The safety and effectiveness of CAMBIA have not been established for cluster headache, which is present in an older, predominantly male population. CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older ( 1 ) Limitations of Use ( 1 ): CAMBIA is not indicated for the prophylactic therapy of migraine Safety and effectiveness of CAMBIA not established for cluster headache, which …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 022165

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 022165
Product	Strength	Form · route	Labeler	Product NDC
Diclofenac Potassium	Diclofenac potassium 50 mg/1	Powder, For solutionOral	Leading Pharma, LLC	69315-506